Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study.
Christian SchwabeChris WynneDayaker Reddy DyapaArpitkumar PrajapatiDisha DadkePublished in: Oncology and therapy (2024)
ANZCTR number: ACTRN12621000573853.